Teikoku Tsushin Kogyo Co.,Ltd. Q4 FY2025 earnings call

Core Company Strengths

• Integrated in-house production: Capable of handling custom to general-purpose products, from product design, mold design and processing, to final assembly centered on unique film printing and molding/pressing technologies. This allows cost control, collaborative problem-solving with clients, and delivery of high-value-added solutions.
• Element technology foundation: Core technology rooted in resistor printing and resistor formulation, which has evolved from original variable/fixed resistor products to develop front operation blocks and a broad line of sensors that are adopted across multiple end markets. The company continues to expand share in existing markets through performance improvements and cost competitiveness, while actively pursuing new market opportunities.
• Dual product portfolio: Split between custom ICB products tailored to client-specific requirements and general-purpose discrete electronic components, serving a broad base of customers.

Operational Progress and Investments

• Production automation: Invested in in-house developed image processing technology to automate manual inspection and printing processes, addressing challenges of high-mix low-volume production, reducing quality variability, cutting inspection costs, improving printing accuracy, reducing setup changeover time, and boosting overall productivity. Rollout to additional factories is planned.
• New product development in growth segments:
  • Automotive electronics: Developing high-precision, high-durability sensors including door mirror sensors, HVAC actuator sensors (used in automatic air conditioning, with increasing per-vehicle adoption regardless of vehicle powertrain), pre-charge/discharge resistors, and transparent electrode sheets for EV and conventional vehicles alike.
  • Medical/Healthcare: Developing biocompatible electrodes and conductive gels for ECG/EMG/EEG measurement, with ongoing joint university research preparing product launch for polysomnography testing for sleep apnea. Developing point-of-care testing (POCT) electrochemical sensors for at-home/on-site health testing, including sodium/potassium level sensors, creatinine sensors for cardiac function testing, and gut health sensors.
  • New growth areas: Developing water leakage sensors, currently in joint research with aquariums to deliver real-time leak alerts, with the goal of building know-how for future commercialization. Targets future expansion into agribusiness as a new growth area.
• Capital and Financial Strategy:
  • FY2025 total assets reached 33.5 billion yen, with liquidity of 13.1 billion yen, an equity ratio of 83.1%, maintaining a strong, conservative balance sheet. The company targets balancing financial soundness with improved capital efficiency, planning to continue limiting excess net asset growth via shareholder returns including potential additional treasury stock purchases.
  • Cumulative cash allocation over the current mid-term plan: 2.9 billion yen from asset sales (primarily policy-held stock) and 13.3 billion yen from operating cash flow as total cash inflow. 7.6 billion yen allocated to capital investment, 2.7 billion yen to R&D, 4.7 billion yen to shareholder returns, with 2.1 billion yen carried forward for the next mid-term plan. Going forward, the company plans to reduce policy-held stock holdings to below 10% of consolidated net assets by FY2027 to free up capital.
• Infrastructure Development: Construction of the new head office and R&D facility is progressing on schedule, with above-ground demolition completed and underground demolition underway. This investment is to support advanced R&D and next-generation product manufacturing, with additional factory expansion for high-value product manufacturing under consideration for the future.
• Capital Market and IR Strategy: The company has seen its share price rise from ~1,200 yen at the launch of the current mid-term plan to sustain above 2,000 yen, with PBR approaching 1x. ROE reached 7.4% in FY2025, close to the 8% target. The company continues to pursue three priorities: improving earnings power via expansion into new markets, optimizing capital structure via shareholder returns, and improving market multiple via enhanced IR and sustainability disclosure. It has expanded IR staffing to meet growing institutional investor engagement.

The company operates a single Electronic Components segment, with all revenue broken out by market and product category: Market-based revenue (FY2025 March):

1. AV Equipment: 24% of total segment revenue, with strong growth driven by mirrorless interchangeable-lens cameras, reaching an absolute revenue level that outpaced prior year results, contributing a 2 percentage point increase in revenue share year-over-year.
2. Automotive: 20% of total segment revenue, absolute revenue grew year-over-year, with a 2 percentage point share decline from the prior year due to faster overall segment growth.
3. Amusement: Solid growth in FY2025, but order volumes are expected to moderate in FY2026.
4. Home Appliance, Industrial Machinery, and Medical Healthcare: All delivered steady revenue growth in FY2025, with continued steady growth expected in FY2026.

Product-based revenue (FY2025 March):

1. ICB (Custom Front Operation Block Products): Legacy core product with steady performance.
2. Sensors: Grew to match ICB in revenue scale, establishing as a new core revenue pillar for the company, driven by expanding market demand.
3. Discrete Products (general-purpose variable resistors, fixed resistors, switches): Maintained steady sales.
4. Other products: Delivered strong revenue growth in FY2025, primarily driven by expanding sales of environmentally friendly cushioning materials.

Full year FY2025 March consolidated results: Total revenue of 16.7 billion yen, operating profit of 1.663 billion yen, representing a 10% year-over-year revenue increase and a 75% year-over-year operating profit increase. Operating profit margin reached 10%.

• For FY2026 March (full year, the final year of the current 5-year mid-term management plan):
  • Revenue guidance is 17.0 billion yen (year-over-year increase), operating profit guidance is 1.5 billion yen (year-over-year decrease), with an expected operating margin of 8.8%. The operating profit decline is entirely due to the assumed yen appreciation (forecast assumption of 1 USD = 140 JPY); excluding foreign exchange impact, both revenue and operating profit would see year-over-year growth.
  • Ordinary income guidance is 1.6 billion yen (a 527 million yen year-over-year decrease driven by the absence of FY2025 non-recurring gains from foreign exchange and fixed asset sales), and net income attributable to parent shareholders is 1.3 billion yen (a 709 million yen year-over-year decrease driven by the absence of FY2025 tax accounting classification adjustment gains).
  • The 5-year current mid-term management plan is on track to exceed 100% cumulative revenue and operating profit target achievement if FY2026 guidance is met.
  • Full year dividend guidance is maintained at 100 yen per share, unchanged from FY2025. Starting from the next mid-term plan, the company will target a consolidated payout ratio of at least 50%.
• Long-term growth guidance: The company targets accelerating growth in new core areas of automotive electronics, medical/healthcare, and new emerging areas to build out future revenue pillars, supported by continued targeted investment in R&D and manufacturing infrastructure. The long-term ROE target is 8% to exceed the cost of equity.

• High reciprocal tariffs between the US and other countries (including China) create high uncertainty for supply chain planning and future order trends, with visibility remaining limited.
• EV sales have seen a recent slowdown in the automotive market, though the overall market remains steady.
• FA equipment and capital investment-related segments of the industrial machinery market continue to undergo inventory adjustment, which near-term demand.
• Rising raw material prices and increasing personnel/operating costs are persistent headwinds that put upward pressure on total costs.
• While ROE has improved, it remains below the company's 8% target, and PBR also remains below the 1x target, requiring continued improvement in capital efficiency and market valuation.

No Q&A section was included in the provided transcript content.